Fact CheckerSign in

NCT06971965Not yet recruiting

Necessity of TSH Suppression Therapy in Active Surveillance for Thyroid Cancer Patients.

Source: ClinicalTrials.gov · Last updated 14 May 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This study is a multicenter randomized controlled trial conducted in Korea. A parallel, two-group randomized design will be with thyroid stimulating hormone suppression therapy group(low TSH group; intervention) is different from the wIthout thyroid stimulating hormone (TSH) suppression therapy group(high TSH group; control).

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
578 (estimated)
First submitted
27 Apr 2025
Start date
2 Jun 2025
Primary completion date
31 Dec 2027
Lead sponsor
National Cancer Center, Korea
NCT number
NCT06971965

What you commit to

  • Study type: Interventional
  • Planned participants: 578
  • From 2 Jun 2025 to the primary completion date, 31 Dec 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • If the investigator determines that you are not suitable for clinical research participation considering the following comorbidities:
    • Myocardial infarction or cerebrovascular accident within the last three months.
    • Diseases with limited life expectancy or potentially impairing the patient's ability to comply with at least five years of treatment or follow-up.

Other

  • Hyperthyroidism

Who the study is looking for

  • Thyroid nodule of 1.0 cm or less confirmed as Bethesda category V (suspicious for PTC) or VI (PTC) based on cytopathological examination, or Bethesda category III (atypia of undetermined significance) with a confirmed BRAF V600E mutation.
  • Patients with no evidence of distant metastasis, cervical lymph node metastasis, recurrent laryngeal nerve invasion, or tracheal invasion. Additionally, no evidence of extrathyroidal extension (ETE) should be present, and the tumor must not belong to high-risk subtypes of PTC (e.g., diffuse sclerosing, columnar cell, or solid subtype).
  • Non-pregnant women of childbearing potential (confirmed by medical history taking)

Age in the registry: 19 years to 79 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.